Compare Eli Lilly And Co (LLY) vs Monster Beverage Corp (MNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Monster Beverage Corp — how do they compare? Eli Lilly And Co trades at $1,221.25 (market cap $1.08T), while Monster Beverage Corp trades at $46.06 (market cap $89.20B). The key difference: Eli Lilly And Co is far larger — about 12.1× Monster Beverage Corp's market cap, and Eli Lilly And Co pays a 0.57% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals.
| LLY | MNST | |
|---|---|---|
Market Cap | $1.08T | $89.20B |
Sector | Health | Consumer Staples |
52-Week High | $1.24K | $49.97 |
52-Week Low | $639.43 | $30.86 |
Enterprise Value | $1.13T | $87.49B |
Dividend Yield | 0.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.
Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.
Monster Beverage (MNST) trades at $45.895, up 0.45% with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $8.29B and net income of $1.91B, achieving a 23.08% net margin. Recent Q2 2026 results beat expectations with $0.60 EPS versus $0.59 expected, driven by international growth. A 2-for-1 stock split occurred on August 11, 2026, while analyst consensus remains positive with 51% buy ratings and a $51.14 price target.
MNST's outlook is supported by robust earnings growth and global expansion, but elevated valuation ratios (P/E 42.16, P/S 9.75) pose risks. Competitive pressures in the energy drink sector and macroeconomic sensitivity could challenge margins. Institutional sentiment is cautiously optimistic, with upside potential to the consensus target representing 11% gain from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
